LEO Pharma to Acquire Dersimelagon Rights from Tanabe for Up to $435 Million
LEO Pharma announced it will acquire worldwide rights to the dersimelagon candidate from Tanabe Pharma for up to $435 million in upfront and near-term milestones. The deal signals a potential expansion of LEO's dermatology portfolio and future revenue if dersimelagon progresses. Details on indication, development stage, and timing were not disclosed, creating near-term uncertainty but potential long-term pipeline value.
View signal analysis